Latanelb (Latanoprost)

Latanoprost mimics prostaglandin F2α and activates FP receptors in the ciliary body. This activation increases uveoscleral outflow of aqueous humor, facilitating drainage from the eye and thereby reducing intraocular pressure.

The dosing regimen for Latanelb is determined by the prescribing ophthalmologist. Typically, a single drop is instilled in the affected eye(s) once daily in the evening, but the exact dose and timing are individualized for each patient.

Safety data for latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost is often preferred for its once‑daily dosing and strong intraocular pressure‑lowering effect. Compared with beta‑blocker drops, it has a different side‑effect profile, such as increased eyelash growth, and may be used when beta‑blockers are contraindicated or insufficient.

Latanelb should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light and moisture, and discard any solution that appears discolored or contaminated.

Latanelb is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac of the affected eye(s). Close the eye gently and avoid blinking excessively for a few minutes.

Serious risks include uveitis, corneal edema, macular edema, and severe allergic reactions that may threaten vision. Patients should report any sudden eye pain, redness, vision changes, or swelling to their eye‑care professional promptly.

Latanelb is contraindicated in patients with active intraocular inflammation (uveitis), known hypersensitivity to latanoprost or any component of the formulation, and in those with certain corneal disorders where increased outflow could worsen the condition.